Evinacumab

Evinacumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetAngiopoietin-like 3 (ANGPTL3)
Clinical data
Trade namesEvkeeza
Other namesREGN1500, evinacumab-dgnb
AHFS/Drugs.comEvkeeza
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6480H9992N1716O2042S46
Molar mass146083.95 g·mol−1

Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).[4][5][6]

Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.[5]

Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).[5] ANGPTL3 slows the function of certain enzymes that break down fats in the body.[5] Evinacumab blocks ANGPTL3, allowing faster break down of fats that lead to high cholesterol.[5] Evinacumab was approved for medical use in the United States in February 2021.[5][9][10] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[11]

  1. ^ "Details for: Evkeeza". Health Canada. 21 November 2023. Retrieved 3 March 2024.
  2. ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
  3. ^ "Summary Basis of Decision (SBD) for Evkeeza". Health Canada. 8 February 2024. Retrieved 24 February 2024.
  4. ^ a b "Evkeeza- evinacumab injection, solution, concentrate". DailyMed. Retrieved 14 September 2021.
  5. ^ a b c d e f g "FDA approves add-on therapy for patients with genetic form of severely". U.S. Food and Drug Administration (FDA). 11 February 2021. Retrieved 12 February 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ a b "Drug Trial Snapshot: Evkeeza". U.S. Food and Drug Administration. 22 November 2022. Retrieved 23 November 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ Cite error: The named reference Evkeeza EPAR was invoked but never defined (see the help page).
  8. ^ "Evkeeza Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  9. ^ "FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol" (Press release). Regeneron Pharmaceuticals. 11 February 2021. Retrieved 12 February 2021 – via PR Newswire.
  10. ^ "Drug Approval Package: Evkeeza". U.S. Food and Drug Administration (FDA). 11 March 2021. Retrieved 13 September 2021.
  11. ^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.